Optimization of antimalarials targeting multiple life stages of the parasite
Active Project Grant Awarded Last action
- Award ID
- R01AI157445
- Recipient
-
University Of Illinois UEI W8XEAJDKMXH3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,951,491
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 52% complete
- Originally
- Funding
-
- $11,183,298.00 Federal
- $768,193.00 Non-federal
- Place of performance
- Chicago, IL 60612, USA
Award details come from USAspending.gov.
Description
- Abstract
- The malaria parasite is one of the most deadly eukaryotic pathogens and more than 40% of the world's population is at risk of contracting malaria. Due to growing resistance to currently available medications, there is a pressing medical need for new drugs to prevent and treat malaria infection. This grant application focuses on the optimization of two novel antimalarials (2A and (R)-3A) to target multiple life stages of the parasite that emerged from our previous work on the malaria box compound MMV008138 that targets the apicoplast. These compounds were identified using a combination of atomic property field-based virtual ligand screening (VLS) of a library of 5 million publicly available compounds and synthetic chemistry campaigns. Although 2A and (R)-3A bear a structural resemblance to MMV008138 and kill asexual blood-stages, their mechanism of action is independent of the apicoplast. In addition, whereas MMV008138 only affects asexual blood-stages, 2A also kills stage V gametocytes, and (R)-3A weakly kills plasmodium berghei liver-stages. For each of the two novel compound series, we will explore: I) structure activity relationships that control potency, cellular selectivity, and efficacy; II) structure property relationships that govern adsorption, distribution, metabolism, and excretion; and III) their potential mechanisms of action and resistance. The overarching goal of this project is to prioritize preclinical leads having novel mechanism of action, high selectivity for plasmodium versus the human host, and physiochemical properties that are compatible with development of an orally available drug candidate. The two principal goals of this R01 proposal are to: 1) structurally modify 2A (LEAD) and (R)-3A (HIT) to optimize in vitro asexual blood-stage potencies in addition to gametocicydal and/or liver stage activities, drug-like properties, and pharmacokinetics, achieving in vivo P. Berghei-infected mice efficacy with a single oral dose ED90 = 10 MG/KG for the 2A analogs (late LEAD) and an ED90 = 40 MG/KG/day with 1-3 oral doses for the (R)-3A series (early LEAD), and 2) identify the antimalarial mechanisms of action and resistance of 2A and (R)-3A (or their more potent analogs) by chemoproteomic and resistance-selection approaches, respectively. The ancillary goal of this proposal is to develop structure-activity relationships (SAR) for the P. Falciparum gametocytocidal potency and P. Berghei liver-stage potency of these two series, and to determine consensus pharmacophores for multi-stage activities (asexual blood-stage potencies plus gametocytocidal and/or liver-stage potencies). Efficacious compounds identified in this way will thus be well-positioned for further preclinical development.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $782,108 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $688,004 | $0 | |
| Amendment | $688,004 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $60,972 | $0 | |
| Amendment | $60,972 | $0 | |
| Amendment | $60,972 | $0 | |
| Amendment | $709,897 | $0 | |
| Amendment | $709,897 | $0 | |
| Amendment | $709,897 | $0 | |
| Amendment | $709,897 | $0 | |
| Amendment | -$209,448 | $0 | |
| Amendment | $209,448 | $0 | |
| Amendment | $75,947 | $0 | |
| Amendment | $75,947 | $0 | |
| Amendment | $707,225 | $0 | |
| Amendment | $707,225 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $724,987 | $0 | |
| Amendment | -$715,213 | $0 | |
| Amendment | $724,987 | $0 | |
| Amendment | -$715,213 | $0 | |
| Amendment | -$715,213 | $0 | |
| Amendment | $724,987 | $0 | |
| Amendment | $724,987 | $0 | |
| Amendment | -$715,213 | $0 | |
| Amendment | $715,213 | $0 | |
| Amendment | $715,213 | $0 | |
| Amendment | $715,213 | $0 | |
| Amendment | $715,213 | $0 | |
| Amendment | $768,193 | $0 | |
| Original award | $768,193 | $768,193 |
Show all 42
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Georgia Research Foundation, Inc. | $60,972 | |
| Molsoft L.L.C. | $216,057 | |
| University Of Georgia Research Foundation, Inc. | $1,333,666 |
Quick answers
Who received award R01AI157445?
R01AI157445 was awarded to University Of Illinois by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 4, 2021.
How much is award R01AI157445 worth?
$11,951,491 has been obligated on R01AI157445: $11,183,298 in federal funding and $768,193 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award